Informations relatives aux psychotropes et à leurs adaptations éventuelles pour les patients souffrant de troubles psychiques en France pendant l’épidémie à SARS-CoV-2

Javelot, Hervé; Llorca, P.M.; Drapier, Dominique; Fakra, Éric; Hingray, Coraline; Meyer, Guillaume; Dizet, Sophie; Egron, A.; Straczek, Céline; Roser, Mathilde; Masson, M; Gaillard, Raphaël; Fossati, Philippe; Haffen, Emmanuel

doi:10.1016/j.encep.2020.04.006

Cited by 18 publications

(12 citation statements)

References 66 publications

(97 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Les facteurs incriminés seraient, notamment, une réduction des temps d'activité physique, une diminution des rapports sociaux, une désynchronisation du rythme circadien, et des temps d'ennui prolongé [2,3]. Parallèlement, les services de soins connaissent des modifications massives de leurs organisations, notamment en psychiatrie [4].…”

Section: Introductionunclassified

Comment les enfants et adolescents avec le trouble déficit d’attention/hyperactivité (TDAH) vivent-ils le confinement durant la pandémie COVID-19 ?

Bobo

Lin

Acquaviva³

et al. 2020

L'Encéphale

151

View full text Add to dashboard Cite

show abstract

Section: Introductionunclassified

Comment les enfants et adolescents avec le trouble déficit d’attention/hyperactivité (TDAH) vivent-ils le confinement durant la pandémie COVID-19 ?

Bobo

Lin

Acquaviva³

et al. 2020

L'Encéphale

151

View full text Add to dashboard Cite

show abstract

“…One of our patients (#8), who was on long-term treatment with carbamazepine received hydroxychloroquine. Though carbamazepine is not recommended together with COVID-19 treatment due to its hepatic enzyme induction (Javelot et al 2020), we decided not to cut it down, because of the positive response of the patient's impulsivity and other symptoms to carbamazepine before. Symptoms and pulmonary CT findings of the patient have markedly improved with the treatment, and no side effects have been observed.…”

Section: Discussionmentioning

confidence: 99%

Adverse drug reactions associated with concurrent acute psychiatric treatment and Covid-19 drug therapy

Güngör¹,

Yalçın²,

Tüzer³

et al. 2020

International Journal of Psychiatry in Clinical Practice

View full text Add to dashboard Cite

Objective: Psychiatric patients are at increased risk of contamination, morbidity, and mortality associated with COVID-19, together with potentially more pronounced adverse effects. We present and discuss the adverse effects observed in an acute psychiatric clinic that has admitted COVID-19 patients during the first three months of the pandemic in Turkey. Methods: The COVID-19 treatment schemes were formed in accordance with the national and regional guidelines at the time of admittance, which were mainly based on the use of hydroxychloroquine and other drugs. The sample consisted exclusively of inpatients, and all patients were enrolled in the study regardless of their specific diagnosis or treatment schemes. Results: 4 out of 23 patients (17.4%) had experienced adverse effects, two of which had mild hepatic enzyme elevation and one had mild sinus bradycardia. Of note is that we haven't encountered any serious complications or life-threatening events during inpatient treatment. The most emphasised adverse effect in the literature, namely QTc prolongation and ECG changes, were not observed in our sample. The adverse effects were not found to be significantly associated with patient-related factors nor dose of antipsychotic medication. Conclusions: From our point of view, non-cardiac adverse effects should not be overlooked while treating comorbid psychiatric and COVID-19 patients. KEY POINTSAcute inpatient psychiatric treatment of patients who have comorbid COVID-19 is a complex situation requiring multidisciplinary action. Adverse drug reactions, which may or not result from the interaction of psychiatric and COVID-19 treatment, should be of concern for this patient group. While there is controversy over the benefits of some of the off-label COVID-19 medications, there should also be discussion over safety and concomitant medication use. In order to be adequately prepared for future escalations of COVID-19 pandemic, psychiatric services should thoroughly evaluate their initial experience with COVID-19, including from the point of drug effectiveness and safety.

show abstract

“…In the French government’s recommendations concerning COVID-19, the consumption of inhaled cannabis products was mentioned as potentially promoting the onset of coughing and thus increasing transmission of the virus, particularly in the case of asymptomatic infections, as well as in intensifying COVID-19 respiratory symptoms. In addition, cannabis can alter the vigilance level and thus may aggravate central symptoms of COVID-19, such as fatigue and confusion [40].…”

Section: The Role Of Ecs Cannabinoids and Cannabis In Sars-cov-2 Inmentioning

confidence: 99%

Cannabinoids and COVID-19

Biali

Broers

Besson

et al. 2020

Med Cannabis Cannabinoids

View full text Add to dashboard Cite

Since the endocannabinoid system is involved in immune function, the effect of cannabinoid intake on infectious conditions is questioned for several years and is of particular interest in the COVID 19 pandemia. Some data suggest that the immunomodulatory effect of cannabinoids may affect the course and severity of SARS-CoV-2 infection. Given the large number of cannabinoids consumers in the community, this commentary presents the current knowledge on the potential impact of cannabinoids and endocannabinoids on bacterial and viral infection courses namely SARS-CoV-2 disease. Practical recommendations, which can be drawn from the literature, are given.

show abstract

Informations relatives aux psychotropes et à leurs adaptations éventuelles pour les patients souffrant de troubles psychiques en France pendant l’épidémie à SARS-CoV-2

Cited by 18 publications

References 66 publications

Comment les enfants et adolescents avec le trouble déficit d’attention/hyperactivité (TDAH) vivent-ils le confinement durant la pandémie COVID-19 ?

Comment les enfants et adolescents avec le trouble déficit d’attention/hyperactivité (TDAH) vivent-ils le confinement durant la pandémie COVID-19 ?

Adverse drug reactions associated with concurrent acute psychiatric treatment and Covid-19 drug therapy

Cannabinoids and COVID-19

Contact Info

Product

Resources

About